Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan

Next Previous
Trial Profile

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atrasentan (Primary)
  • Indications Diabetic nephropathies
  • Focus Registrational; Therapeutic Use
  • Acronyms SONAR
  • Sponsors AbbVie

    • Most Recent Events

    • 01 Dec 2023 Results of post hoc analysis assessing association between the endothelin receptor antagonist atrasentan and pain and prescription of analgesics published in the Kidney International
    • 23 Mar 2023 According to a Chinook Therapeutics media release, data from this study will be presented at the ISN World Congress of Nephrology 2023 on Saturday, April 1, 2023 at 17:00-18:00 ICT.
    • 27 Jul 2022 Results assessing the influence of genetic polymorphisms on atrasentan plasma exposure and pharmacodynamic effects, published in the Clinical Pharmacology and Therapeutics.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top